For Intarcia Therapeutics, which wanted to retain 100% of the domestic rights to its once-yearly diabetes drug, Servier turned out to be the best possible partner to commercialize ITCA 650 in foreign markets given the French pharmaceutical firm's long-standing aversion to the US market.
The two private companies negotiated an agreement worth up to $1bn for global rights, excluding the US and Japan, for...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
